Related Patent Info

The objective of the present invention is to provide a low-cost, simple method for preparing cells having pluripotency and extremely low tumorigenic risk. Human mesenchymal stem cells from bone marrow (hMSC-BM), human adipose tissue-derived mesenchymal stem cells (hAT-MSC) (also known as "human adipose-derived stem cells (hADSC)")and other such mammal mesenchymal stem cells are cultured in suspension with 7 types of human adherent mature cell (human hepatocyte cells [hHEP cells], human umbilical vein endothelial cells [HUVEC cells], human dermal microlymphatic endothelial cells [HMVEC cells], human epidermal keratinocyte cells [NHEK cells], human bronchial epithelial cells [NHBE cells], human melanocyte cells [NHEM cells], and human smooth muscle cells [UASMC cells]) and 3 types of human adherent precursor cell (human dermal fibroblast cells [NHDF], human skeletal muscle myoblast cells [HSMM cells], and human osteoblast cells [NHOst cells]) in order to form a mass of cells (spheroid), thereby enabling the preparation of cells having pluripotency and extremely low tumorigenic risk.